Experienced in Congenital Antithrombin 3 Deficiency

Chih-cheng R. Wu

Hsin Chu Branch, 
Hsinchu, TNQ, TW 
Experienced in Congenital Antithrombin 3 Deficiency
Hsin Chu Branch, 
Hsinchu, TNQ, TW 
OverviewLocationsClinical Research

Overview

Chih-cheng Wu practices in Hsinchu, Taiwan. Wu is rated as an Experienced expert by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Their top areas of expertise are Acute Coronary Syndrome, Japanese Encephalitis, Arterial Insufficiency, Angioplasty, and Thrombectomy.

Their clinical research consists of co-authoring 131 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Congenital Antithrombin 3 Deficiency.

Locations

Hsin Chu Branch, Hsinchu, TNQ, Taiwan
Other Locations
Hsinchu Branch, TPQ, Taiwan
Hsinchu Branch, Hsinchu, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 4

131 Total Publications

Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.
Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
      View All 31 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile